Mexico’s Legalization of Medical Marijuana Yields Opportunities


Ryan Allway

May 25th, 2017

News, Top News


The Mexican government took a giant leap forward in the legalization of medical marijuana after Congress passed a bill admitting the drug has medicinal and scientific merits. With the country’s moving towards medical and perhaps recreational legalization, investors may want to take a closer look at companies that are focused on selling medical marijuana and related products into the market, such as cannabidiol-based oils and supplements.

In this article, we will look at Mexico’s recent legalization of medical marijuana and why Medical Marijuana Inc. (OTC Pink: MJNA) may be best positioned to profit.

Mexico Approves Medical Marijuana

Mexico’s Lower House of Congress recently passed a bill that legalizes the use of medical marijuana and scientific research. In particular, the bill classifies the controversial psychoactive component of marijuana – tetrahydrocannabinol or THC – as “therapeutic”. The move is akin to the U.S. Drug Enforcement Administration (DEA) rescheduling marijuana to a controlled substance that has therapeutic value for patients.

“The ruling eliminates the prohibition and criminalization of acts related to the medicinal use of marijuana and its scientific research, and those relating to the production and distribution of the plant for these purposes,” read a Congressional statement.

The bill will now be sent to President Enrique Pena Nieto who is expected to sign it into law. While Pena Nieto was once a vocal opponent to legalization, his viewpoint has shifted to view drug use as a “public health problem” where users should not be criminalized. He even proposed a bill last year that would have permitted Mexicans to carry up to an ounce of marijuana, but that measure has since stalled in Congress.

Medical Marijuana Inc. in Mexico

Medical Marijuana Inc. has remained the only legal provider of CBD oils in Mexico through its HempMeds Mexico subsidiary. The company’s Real Scientific Hemp Oil – or RSHO – brand has become synonymous with ultra-high quality and reliability, which is why the government granted the company an exclusive  import license for certain medical conditions including epilepsy and neuropathic pain. At the same time, RSHO-X (RSHO with absolutely no THC) has already been used in clinical studies evaluating the effects of CBD on epilepsy.

In March, HempMeds Mexico held a press conference in Mexico City revealing the positive results of a clinical study conducted by renowned physician Dr. Saul Garza Morales on the effects of RSHO-X in treating children with severe epilepsy. The 39-patient study of children with with Lennox-Gastaut syndrome showed an 84% reduction in motor seizures, 53% improvement in quality of life, and seven individuals that reported a complete elimination of seizures, which was covered by the CW television network.

The combination of a product already on the market and clinical data supporting its efficacy marks a significant competitive advantage compared to other products on the market. Given this early lead, the company is well positioned to capitalize on the market as restrictions are lifted and wider access is granted for cannabidiol and other cannabinoids that may have additional uses across many different medical conditions.

Looking Ahead

Medical Marijuana Inc. (OTC Pink: MJNA) represents a compelling investment opportunity following Mexico’s move to legalize medical marijuana. With an existing license and clinical data in place, the company has a significant competitive edge to new products entering the market and a key advantage when launching future product lines. Investors may want to take a closer look at the stock given these catalysts. The company and the potential were covered by Fortune Magazine.

In addition to HempMeds Mexico, the company owns other investments and subsidiaries across many different areas of the cannabis industry. These businesses operate in both the United States and other countries around the world, including Mexico, Brazil, and Puerto Rico. Investments also include large companies like AXIM Biotechnologies Inc. (OTCQB: AXIM), and Kannalife Sciences which are rapidly advancing innovative cannabinoid pharmaceutical portfolios.

For more information, visit the company’s website or CannabisFN’s company profile.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © TDM Financial LLC · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading